ES2222336T3 - Inhibidores de girasas y sus usos. - Google Patents
Inhibidores de girasas y sus usos.Info
- Publication number
- ES2222336T3 ES2222336T3 ES01903077T ES01903077T ES2222336T3 ES 2222336 T3 ES2222336 T3 ES 2222336T3 ES 01903077 T ES01903077 T ES 01903077T ES 01903077 T ES01903077 T ES 01903077T ES 2222336 T3 ES2222336 T3 ES 2222336T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- aliphatic
- ring
- optionally substituted
- aliphatic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El uso de un compuesto que tiene la fórmula: o de una de sus sales farmacéuticamente aceptables, fórmula en la que R1 es un grupo opcionalmente sustituido, seleccionado entre un grupo alifático(C1-C6), - C(R4)2(CH2)nNRCOR, -C(R4)=N-OR, -C(R4)=N-OC(=O)(grupo alifático(C1-C6)), -C(R4)=NNRCO2(grupo alifático(C1-C6)), -C(R4)=NNRCOR, -C(R4)=NN(R)2, -C(R4)2(CH2)nNRCO2(grupo alifático(C1-C6)), -CO2(grupo alifático(C1-C6)), -CON(R)2, - C(R4)2(CH2)nCON(R)2, -C(R4)2(CH2)nSO2N(R)2, -CONH-OR, - SO2N(R)2, o -C(R4)2(CH2)nNRSO2(grupo alifático C1-C6)); n es cero o uno; cada R se selecciona independientemente entre hidrógeno o un grupo alifático(C1-C6) opcionalmente sustituido; R2 se selecciona entre hidrógeno o, cuando R1 es -CO2(grupo alifático(C1-C3)) o -CONH(grupo alifático(C1- C3)), R2 se selecciona además entre -halo, -CN, -grupo alifático(C1-C4), un heterociclilo de tres a cinco miembros, o un heteroarilo de cinco miembros; el Anillo A es un anillo de heteroarilo seleccionado entre tiazol, oxazol, imidazol o pirazol, en el que dicho imidazol está opcionalmente unido por medio de un puente(C1-C3) desde un nitrógeno del anillo de imidazol a un Ar para formar un anillo fusionado de cinco a siete miembros; Z es C-R3 o N-R3; R3 es -(CH2)pN(R5)2 o un grupo opcionalmente sustituido, seleccionado entre un grupo alifático(C1-C8), heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo; cada R4 se selecciona independientemente entre hidrógeno, un grupo alifático(C1-C6) opcionalmente sustituido, o dos R4, considerados junto con el carbono al que están unidos, forman un anillo alifático de tres a seis miembros; cada R5 se selecciona independientemente entre hidrógeno, un grupo alifático(C1-C4) opcionalmente sustituido, o dos R5, considerados junto con el nitrógeno al que están unidos, forman un anillo heterocíclico de cinco o seis miembros; p es un número entero de cero a cuatro cuando Z es C-R3, o un número entero de uno a cuatro cuando Z es N- R3; y Ar es unanillo de arilo, heteroarilo o heterociclilo, opcionalmente sustituido, para la preparación de una composición farmacéutica para tratar una infección bacteriana en un mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17667100P | 2000-01-18 | 2000-01-18 | |
US25433100P | 2000-12-08 | 2000-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2222336T3 true ES2222336T3 (es) | 2005-02-01 |
Family
ID=26872470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01903077T Expired - Lifetime ES2222336T3 (es) | 2000-01-18 | 2001-01-16 | Inhibidores de girasas y sus usos. |
Country Status (23)
Country | Link |
---|---|
US (2) | US6608087B1 (es) |
EP (1) | EP1251848B1 (es) |
JP (1) | JP2003520233A (es) |
CN (1) | CN1230166C (es) |
AR (1) | AR027518A1 (es) |
AT (1) | ATE269701T1 (es) |
AU (1) | AU782883B2 (es) |
BR (1) | BR0107713A (es) |
CA (1) | CA2397686A1 (es) |
CO (1) | CO5261612A1 (es) |
DE (1) | DE60103974T2 (es) |
DK (1) | DK1251848T3 (es) |
EA (1) | EA005680B1 (es) |
ES (1) | ES2222336T3 (es) |
HK (1) | HK1053984B (es) |
MX (1) | MXPA02007134A (es) |
MY (1) | MY133572A (es) |
NZ (1) | NZ520628A (es) |
PT (1) | PT1251848E (es) |
SI (1) | SI1251848T1 (es) |
TR (1) | TR200401735T4 (es) |
TW (1) | TWI287449B (es) |
WO (1) | WO2001052845A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088101A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
PL210475B1 (pl) * | 2001-08-13 | 2012-01-31 | Janssen Pharmaceutica Nv | Pochodna 2,4,5-tripodstawionego tiazolilu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
FR2865733B1 (fr) * | 2004-02-04 | 2007-10-12 | Merck Sante Sas | Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine |
EP1819721A1 (en) * | 2004-11-19 | 2007-08-22 | Plant Bioscience Limited | Microcin b17 analogs and methods for their preparation and use |
CN101163693B (zh) | 2005-02-18 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
WO2007097940A2 (en) * | 2006-02-13 | 2007-08-30 | Trustees Of Boston University | Reca inhibitors with antibiotic activity, compositions and methods of use |
JP5269779B2 (ja) | 2006-06-21 | 2013-08-21 | クック・バイオテック・インコーポレーテッド | 胃腸瘻の治療に有用な瘻グラフト及び関連する方法とシステム |
US20100234348A1 (en) * | 2006-08-04 | 2010-09-16 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
TW200906412A (en) * | 2007-06-12 | 2009-02-16 | Astrazeneca Ab | Piperidine compounds and uses thereof |
EP2217588A4 (en) * | 2007-11-02 | 2013-12-04 | Methylgene Inc | INHIBITORS OF HISTONE DEACETYLASE |
EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
KR20130040258A (ko) * | 2008-03-21 | 2013-04-23 | 노파르티스 아게 | 신규한 헤테로시클릭 화합물 및 그의 용도 |
US8865732B2 (en) * | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
JPWO2010007943A1 (ja) * | 2008-07-17 | 2012-01-05 | 旭化成ファーマ株式会社 | 含窒素複素環化合物 |
PE20110843A1 (es) | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
TW201026694A (en) | 2008-12-12 | 2010-07-16 | Astrazeneca Ab | Compound 468 |
TW201026695A (en) | 2008-12-12 | 2010-07-16 | Astrazeneca Ab | Piperidine compounds and uses thereof-596 |
CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
US9090601B2 (en) * | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
TW201102065A (en) | 2009-05-29 | 2011-01-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
TW201111380A (en) | 2009-08-26 | 2011-04-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
BR112012014884A2 (pt) * | 2009-12-17 | 2016-03-22 | Merck Patent Gmbh | inibidores de esfingosina quinase |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
PE20131304A1 (es) | 2010-08-11 | 2013-11-14 | Millennium Pharm Inc | Heteroarilos y sus usos |
WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
TW201307309A (zh) | 2010-10-13 | 2013-02-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
CN102911173A (zh) * | 2012-11-08 | 2013-02-06 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
JP2017504662A (ja) | 2014-02-03 | 2017-02-09 | スペロ ジャイレース インク | ポリミキシンを含む抗菌剤の組合せ |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
JPWO2018174288A1 (ja) | 2017-03-24 | 2020-01-23 | 大正製薬株式会社 | 2(1h)−キノリノン誘導体 |
US11666555B2 (en) | 2017-05-17 | 2023-06-06 | Drexel University | RelA inhibitors for biofilm disruption |
US20210323957A1 (en) | 2018-09-03 | 2021-10-21 | Univerza V Ljubljani | New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria |
WO2022129327A1 (en) | 2020-12-17 | 2022-06-23 | Univerza V Ljubljani | New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925659A (en) * | 1996-05-07 | 1999-07-20 | Merck & Co., Inc. | Antibacterial agents |
EP0913151B1 (en) * | 1996-05-09 | 2002-09-04 | Sankyo Company, Limited | Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient |
-
2001
- 2001-01-16 PT PT01903077T patent/PT1251848E/pt unknown
- 2001-01-16 SI SI200130127T patent/SI1251848T1/xx unknown
- 2001-01-16 DE DE60103974T patent/DE60103974T2/de not_active Expired - Lifetime
- 2001-01-16 JP JP2001552893A patent/JP2003520233A/ja active Pending
- 2001-01-16 TR TR2004/01735T patent/TR200401735T4/xx unknown
- 2001-01-16 WO PCT/US2001/001374 patent/WO2001052845A1/en active IP Right Grant
- 2001-01-16 ES ES01903077T patent/ES2222336T3/es not_active Expired - Lifetime
- 2001-01-16 DK DK01903077T patent/DK1251848T3/da active
- 2001-01-16 EA EA200200769A patent/EA005680B1/ru not_active IP Right Cessation
- 2001-01-16 CN CNB018050425A patent/CN1230166C/zh not_active Expired - Fee Related
- 2001-01-16 NZ NZ520628A patent/NZ520628A/en not_active IP Right Cessation
- 2001-01-16 MX MXPA02007134A patent/MXPA02007134A/es active IP Right Grant
- 2001-01-16 BR BR0107713-9A patent/BR0107713A/pt not_active IP Right Cessation
- 2001-01-16 CA CA002397686A patent/CA2397686A1/en not_active Abandoned
- 2001-01-16 AU AU30940/01A patent/AU782883B2/en not_active Ceased
- 2001-01-16 EP EP01903077A patent/EP1251848B1/en not_active Expired - Lifetime
- 2001-01-16 AT AT01903077T patent/ATE269701T1/de not_active IP Right Cessation
- 2001-01-17 MY MYPI20010220A patent/MY133572A/en unknown
- 2001-01-18 AR ARP010100229A patent/AR027518A1/es unknown
- 2001-01-18 CO CO01003497A patent/CO5261612A1/es unknown
- 2001-03-05 TW TW090101034A patent/TWI287449B/zh not_active IP Right Cessation
-
2002
- 2002-07-18 US US10/198,407 patent/US6608087B1/en not_active Expired - Fee Related
-
2003
- 2003-03-24 US US10/395,331 patent/US6930116B2/en not_active Expired - Fee Related
- 2003-09-05 HK HK03106328.7A patent/HK1053984B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TR200401735T4 (tr) | 2004-08-23 |
US6608087B1 (en) | 2003-08-19 |
MXPA02007134A (es) | 2003-03-27 |
PT1251848E (pt) | 2004-10-29 |
JP2003520233A (ja) | 2003-07-02 |
ATE269701T1 (de) | 2004-07-15 |
DE60103974D1 (de) | 2004-07-29 |
CO5261612A1 (es) | 2003-03-31 |
HK1053984B (zh) | 2006-07-28 |
DE60103974T2 (de) | 2005-06-30 |
NZ520628A (en) | 2004-05-28 |
BR0107713A (pt) | 2002-11-19 |
CN1230166C (zh) | 2005-12-07 |
AU782883B2 (en) | 2005-09-08 |
EP1251848B1 (en) | 2004-06-23 |
MY133572A (en) | 2007-11-30 |
US20040024030A1 (en) | 2004-02-05 |
DK1251848T3 (da) | 2004-10-18 |
AU3094001A (en) | 2001-07-31 |
HK1053984A1 (en) | 2003-11-14 |
EA200200769A1 (ru) | 2002-12-26 |
EP1251848A1 (en) | 2002-10-30 |
US6930116B2 (en) | 2005-08-16 |
WO2001052845A1 (en) | 2001-07-26 |
CA2397686A1 (en) | 2001-07-26 |
EA005680B1 (ru) | 2005-04-28 |
TWI287449B (en) | 2007-10-01 |
CN1400898A (zh) | 2003-03-05 |
AR027518A1 (es) | 2003-04-02 |
SI1251848T1 (en) | 2004-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2222336T3 (es) | Inhibidores de girasas y sus usos. | |
ES2502790T3 (es) | Moduladores de la cinasa Aurora y método de uso | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
RS51047B (sr) | Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola | |
AR054963A1 (es) | Inhibidores de girasas y usos de los mismos | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
CO5550398A2 (es) | 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos | |
UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
CO4940472A1 (es) | Pirazolopirimidonas para la disfuncion sexual | |
AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
AR075209A1 (es) | Derivados de 4-amino-5-oxo-7,8-dihidropirimido (5,4-f) (1,4) oxazepin-6 (5h)-il) fenilo | |
CO6251263A2 (es) | Derivados de bencimidazol e indol sustutuidos por oxadiazol y oxazol como inhibidores de dgat1 | |
AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
NO20070343L (no) | N-(1 -(1 -benzyl-4-fenyl-1 H-imidazol-2-yl)-2,2-dimetylpropyl)benzamid derivater og relaterte forbindelser som kinesin spindelprotein (KSP) inhibitorer for behandling av kreft | |
ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona |